GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MAKO Surgical Corporation (FRA:4M6) » Definitions » Beneish M-Score

MAKO Surgical (FRA:4M6) Beneish M-Score : 0.00 (As of Jun. 25, 2024)


View and export this data going back to . Start your Free Trial

What is MAKO Surgical Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for MAKO Surgical's Beneish M-Score or its related term are showing as below:

During the past 11 years, the highest Beneish M-Score of MAKO Surgical was 0.00. The lowest was 0.00. And the median was 0.00.


MAKO Surgical Beneish M-Score Historical Data

The historical data trend for MAKO Surgical's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MAKO Surgical Beneish M-Score Chart

MAKO Surgical Annual Data
Trend Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 7.01 -2.24 -2.54 -2.72

MAKO Surgical Quarterly Data
Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.25 -2.72 -2.62 -2.74 -3.68

Competitive Comparison of MAKO Surgical's Beneish M-Score

For the Medical Devices subindustry, MAKO Surgical's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MAKO Surgical's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MAKO Surgical's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where MAKO Surgical's Beneish M-Score falls into.



MAKO Surgical Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of MAKO Surgical for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8133+0.528 * 0.9983+0.404 * 2.0935+0.892 * 0.9906+0.115 * 0.8054
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0715+4.679 * -0.2716-0.327 * 1.6258
=-3.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep13) TTM:Last Year (Sep12) TTM:
Total Receivables was €12.25 Mil.
Revenue was 17.026 + 21.395 + 19.153 + 23.034 = €80.61 Mil.
Gross Profit was 12.213 + 12.723 + 14.104 + 15.433 = €54.47 Mil.
Total Current Assets was €73.67 Mil.
Total Assets was €102.19 Mil.
Property, Plant and Equipment(Net PPE) was €16.79 Mil.
Depreciation, Depletion and Amortization(DDA) was €6.69 Mil.
Selling, General, & Admin. Expense(SGA) was €63.48 Mil.
Total Current Liabilities was €29.04 Mil.
Long-Term Debt & Capital Lease Obligation was €0.00 Mil.
Net Income was -15.899 + -14.954 + -7.427 + -4.368 = €-42.65 Mil.
Non Operating Income was -0.006 + -5.257 + -0.523 + 0.14 = €-5.65 Mil.
Cash Flow from Operations was -5.073 + -3.757 + -1.75 + 1.332 = €-9.25 Mil.
Total Receivables was €15.21 Mil.
Revenue was 22.641 + 18.869 + 14.867 + 24.995 = €81.37 Mil.
Gross Profit was 13.35 + 13.796 + 10.714 + 17.034 = €54.89 Mil.
Total Current Assets was €65.40 Mil.
Total Assets was €88.80 Mil.
Property, Plant and Equipment(Net PPE) was €18.53 Mil.
Depreciation, Depletion and Amortization(DDA) was €5.52 Mil.
Selling, General, & Admin. Expense(SGA) was €59.81 Mil.
Total Current Liabilities was €15.52 Mil.
Long-Term Debt & Capital Lease Obligation was €0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(12.254 / 80.608) / (15.209 / 81.372)
=0.15202 / 0.186907
=0.8133

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(54.894 / 81.372) / (54.473 / 80.608)
=0.674606 / 0.675777
=0.9983

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (73.671 + 16.793) / 102.187) / (1 - (65.402 + 18.529) / 88.797)
=0.114721 / 0.054799
=2.0935

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=80.608 / 81.372
=0.9906

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(5.516 / (5.516 + 18.529)) / (6.688 / (6.688 + 16.793))
=0.229403 / 0.284826
=0.8054

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(63.482 / 80.608) / (59.807 / 81.372)
=0.78754 / 0.734983
=1.0715

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 29.04) / 102.187) / ((0 + 15.521) / 88.797)
=0.284185 / 0.174792
=1.6258

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-42.648 - -5.646 - -9.248) / 102.187
=-0.2716

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

MAKO Surgical has a M-score of -3.73 suggests that the company is unlikely to be a manipulator.


MAKO Surgical Beneish M-Score Related Terms

Thank you for viewing the detailed overview of MAKO Surgical's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


MAKO Surgical (FRA:4M6) Business Description

Traded in Other Exchanges
N/A
Address
MAKO Surgical Corporation was incorporated in Delaware in November 2004. The Company is a medical device company that markets its advanced robotic arm solution, joint specific applications for the knee and hip, and orthopedic implants for orthopedic procedures. It offers MAKOplasty, an innovative, restorative surgical solution that enables orthopedic surgeons to consistently, reproducibly and precisely treat patient specific, osteoarthritic disease. The Company currently offers MAKOplasty Partial Knee Arthroplasty, or MAKOplasty PKA, and MAKOplasty Total Hip Arthroplasty, or MAKOplasty THA. MAKOplasty PKA, which requires extraction and replacement of the entire joint, enables resurfacing of one or two specific diseased compartments of the joint, preserving significantly more soft tissue and healthy bone of the knee. MAKOplasty procedures are enabled through its proprietary technology consisting of the components which includes its RIO system, its MAKOplasty applications, and its RESTORIS family of implant systems. The centerpiece of MAKOplasty is the RIO system, its proprietary robotic arm, interactive, orthopedic system, that provides both pre-operative and intra-operative guidance to the orthopedic surgeon, enabling tissue sparing bone removal and accurate implant insertion and alignment. The RIO system consists of two elements: a tactile robotic arm utilizing an integrated bone cutting instrument and a patient specific visualization component. The RIO system, version 2.0 of its Tactile Guidance System, or TGS, represents an important expansion from its first generation TGS, enabling and expanding the MAKOplasty PKA application to multicompartmental resurfacing procedures, allowing orthopedic surgeons to treat degenerative knee osteoarthritis from early-stage, unicompartmental degeneration through mid-stage, multicompartmental degeneration with a modular knee implant system, as well as enabling the MAKOplasty THA application. The Company's MAKOplasty PKA application enables surgeons to isolate and resurface just one or two specific diseased compartments of the joint through a minimally invasive incision, preserving significantly more soft tissue and healthy bone of the knee. The MAKOplasty knee resurfacing procedure is performed by the surgeon using the surgical planning and execution software integrated into its patient specific visualization system. The Company's MAKOplasty THA application utilizes the RIO system's tactile, visual and auditory feedback to assist the surgeon in preparing the acetabulum (hip socket) for optimal placement of the acetabular cup implant. The MAKOplasty THA application allows the surgeon to preoperatively plan the placement of the hip implants on a three dimensional image of a pre-operative CT scan. Its RESTORIS family of knee implants is designed to enable minimally invasive restoration of one or two of the diseased compartments of the knee joint. Its RESTORIS family of knee implants for use in si

MAKO Surgical (FRA:4M6) Headlines

No Headlines